HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options

References

• Akiyama T, Sudo G, Ogawara H, Toyoshima K, Yamamoto T. (1986) The product of the human c-erbB-2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science 232: 1644–1646.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Cervantes A, van de Valde CJH (2003) Gastric cancer: epidemiology, pathology and treatment. Ann. Oncol. 14 (Suppl. 2): ii31–ii36.
   PubMedGoogle Scholar
• Ali MA, Gunduz M, Gunduz E, Tamamura R, Beder LB, Katase N, Hatipoglu OF, Fukushima K, Yamanaki N, Shimizu K, Nagatsuka H. (2010) Expression and mutation analysis of HER2 in head and neck squamous cell carcinoma. Cancer Invest. 28: 495–500.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.
   PubMed Web of Science ®Google Scholar
• Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR. (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br. J. Cancer 100: 487–493.
   PubMed Web of Science ®Google Scholar
• Bartsch R, Wenzel C, Steger GG (2007) Trastuzumab in the management of early and advanced stage breast cancer. Biologics 1: 19–31.
   PubMedGoogle Scholar
• Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 32: 57–65.
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19: 1523–1529.
   PubMed Web of Science ®Google Scholar
• Gravalos C, Marquez A, Garcia-Carbonero R, Rivera F, Colomer R, Sastre J, Velasco A, Alonso V, Ales I, Gomez-Martin C. (2007) Correlation between HER2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. ASCO Gastrointestinal Cancers Symposium, Abstract 89.
   Google Scholar
• Hicks DG, Kulkarni S (2008a) HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129: 263–273.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Kulkarni S (2008b) Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch. Pathol. Lab Med. 132: 1008–1015.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797–805.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. Ca Cancer J. Clin. 60: 277–300.
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T. (2006) Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 12: 229–236.
   PubMed Web of Science ®Google Scholar
• Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 21: 815–819.
   PubMed Web of Science ®Google Scholar
• Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol. Oncol. 100: 101–106.
   PubMed Web of Science ®Google Scholar
• Lordick F, Bang YJ, Kang YK, Otero Reyes D, Manikhas GM, Shen L, Kulikov E, Stoss O, Jorden BWM, Van Cutsem E. (2007) HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur. J. Cancer Suppl. 5: 272, Poster #3541.
   Google Scholar
• Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu- overexpressing breast cancer: a systematic review. Cancer Treat. Rev. 34: 539–557.
   PubMed Web of Science ®Google Scholar
• Mezhir JJ, Tang LH, Coit DG (2010) Neoadjuvant therapy of locally advanced gastric cancer. J. Surg. Oncol. 101: 305–314.
   PubMedGoogle Scholar
• Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894–1902.
   PubMed Web of Science ®Google Scholar
• Oh DS, DeMeester SR (2010) Pathophysiology and treatment of Barrett's esophagus. World J. Gastroenterol. 16: 3762–3772.
   PubMedGoogle Scholar
• , GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) GroupPaoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 303: 1729–1737.
   PubMed Web of Science ®Google Scholar
• Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 51: 1371–1379.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. Ca Cancer J. Clin. 55: 74–108.
   PubMed Web of Science ®Google Scholar
• Pera M, Materola C, Vidal O, Grande L (2005) Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol. 92: 151–159.
   PubMed Web of Science ®Google Scholar
• Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, Pimenta A. (2002) C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int. J. Surg. Pathol. 10: 247–256.
   PubMedGoogle Scholar
• Power DG, Kelsen DP, Shah MA (2010) Advanced gastric cancer–slow but steady progress. Cancer Treat. Rev. 36: 384–392.
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457: 299–307.
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A (2007) The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 17: 798–807.
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16: 273–278.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology, College of American Pathologists. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25: 118–145.
   PubMed Web of Science ®Google Scholar
• Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, Salto-Tellez M (2010) A study of HER2 gene amplification and protein expression in gastric cancer. J. Clin. Pathol. 63: 839–842.
   PubMed Web of Science ®Google Scholar